Try a new search

Format these results:

Searched for:

person:charyd01 or goldfd01 or alin06 or bearal01 or benstj01 or caplin01 or chawlh01 or kaploe01 or kalacs01 or katzl01 or kaufmj10 or langsc01 or liud03 or lowenj01 or mattoa02 or mehtam02 or michaj02 or moderf01 or nazzal01 or scherj02 or skolne01 or soomri01 or tatapv01 or thompn01 or weissj02 or zhdano01

active:yes

exclude-minors:true

Total Results:

819


Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Siriwardana, Amanda; Buizen, Luke; Jun, Min; Kotwal, Sradha; Arnott, Clare; Jardine, Meg J; Levin, Adeera; Heerspink, Hiddo J L; Charytan, David M; Pollock, Carol; Perkovic, Vlado; Neuen, Brendon L
AIM/OBJECTIVE:SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age. METHODS:Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years). A range of adjudicated clinical outcomes were assessed, including major adverse cardiovascular events and CKD progression, as well as safety outcomes. Cox proportional hazards models and Fine and Gray competing risk analysis were used. RESULTS:Among the 14 543 participants, 7927 (54.5%) were <65 years, 5281 (36.3%) were 65 to <75 years and 1335 (9.2%) were ≥75 years. Older participants had higher rates of atherosclerotic cardiovascular disease and heart failure, longer diabetes duration and lower mean eGFR. Reductions in cardiovascular and kidney outcomes with canagliflozin were consistent across age categories (all p trend >0.10), although there was some evidence that effects on cardiovascular death and all-cause death were attenuated with older age (p trend = 0.02 and 0.03, respectively). Although the incidence of adverse events increased with age, effects of canagliflozin on safety outcomes including acute kidney injury, volume depletion, urinary tract infections and hypoglycaemia, were not modified by age (all p trend >0.10). CONCLUSIONS:In patients with varying degrees of kidney function, canagliflozin reduced cardiovascular and kidney outcomes, regardless of age, with no additional safety concerns identified in older patients.
PMID: 39781601
ISSN: 1463-1326
CID: 5805172

Moderate Kidney Dysfunction Independently Increases Sudden Cardiac Arrest Risk: A Community-Based Study

Truyen, Thien Tan Tri Tai; Uy-Evanado, Audrey; Chugh, Harpriya; Reinier, Kyndaron; Charytan, David M; Salvucci, Angelo; Jui, Jonathan; Chugh, Sumeet S
BACKGROUND/UNASSIGNED:Moderate kidney dysfunction is independently associated with increased cardiovascular mortality. Sudden cardiac arrest (SCA) accounts for at least 25% of chronic kidney disease (CKD) mortality. METHODS/UNASSIGNED:(2021 CKD-EPI formula). A population-based SCA study in Southern California was used for validation. RESULTS/UNASSIGNED:eGFR drop below 90 increased SCA risk (OR: 1.24, 95% CI: 1.18-1.31). Similar findings were observed in the validation cohort (817 SCA and 3,249 controls), where moderate CKD was associated with SCA (OR: 1.51, 95% CI: 1.16-1.97). CONCLUSION/UNASSIGNED:Moderate CKD is associated with an increased risk of SCA in the general population. Further research into the potential integration of moderate renal dysfunction into SCA risk stratification are warranted.
PMCID:11952626
PMID: 40162277
CID: 5818702

GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study

Orandi, Babak J; Chen, Yusi; Li, Yiting; Metoyer, Garyn T; Lentine, Krista L; Weintraub, Michael; Bae, Sunjae; Ali, Nicole M; Lonze, Bonnie E; Ren-Fielding, Christine J; Lofton, Holly; Gujral, Akash; Segev, Dorry L; McAdams-DeMarco, Mara
BACKGROUND:Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipients. However, kidney transplant recipients are distinct from GLP-1 receptor agonist trial participants, with longer diabetes duration and severity, greater end-organ damage, increased cardiovascular risk, and multimorbidity. We examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes. METHODS:This USA-based retrospective cohort study included kidney transplant recipients with type 2 diabetes at transplantation and Medicare as their primary insurance from a national registry linked with Medicare claims. Post-transplantation GLP-1 receptor agonist use was identified through Medicare claims. Death-censored graft loss was estimated using the Fine-Gray sub-distribution hazard model and extended Cox models were used for mortality and safety endpoints. Models incorporated inverse probability of treatment weights. To further test whether bias could affect the main results, a cohort was created in which each GLP-1 receptor agonist user was matched with a kidney transplant recipient who had not started a GLP-1 receptor agonist, was alive with a functioning graft, and had accrued the same amount of post-transplant survival time. FINDINGS/RESULTS:Between Jan 1, 2013 and Dec 31, 2020, we identified 44 536 first time kidney transplant recipients with Medicare as primary payer in the 6 months before and at transplantation. 24 192 patients were excluded as they did not have type 2 diabetes. 2328 patients were ineligible (1916 had missing values and 412 used GLP-1 receptor agonists before transplantation). The primary cohort thus consisted of 18 016 kidney transplant recipients with diabetes. Of these patients, 1969 (10·9%) had at least one GLP-1 receptor agonist prescription filled post-transplant. Compared with patients who had not received a GLP-1 receptor agonist, GLP-1 receptor agonist users were younger (median age at transplant 57 years [IQR 49-64] vs 60 years [51-66], p<0·0001) and more likely to be female (786 [39·9%] vs 5645 [35·2%], p<0·0001). Among GLP-1 receptor agonist users, 552 [28·0%] were non-Hispanic White, 703 [35·7%] were non-Hispanic Black, and 568 [28·8%] were Hispanic. The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 receptor agonist initiation was 6·0% for GLP-1 receptor agonist users and 10·7% for non-users (Gray's test p=0·004). The 5-year unadjusted cumulative incidence for mortality from a cohort matched on survival time before GLP-1 receptor agonist initiation was 17·0% for GLP-1 receptor agonist users and 25·8% for non-users (log-rank p=0·0006). The 5-year unadjusted cumulative incidence for mortality was 13·5% for GLP-1 receptor agonist users and 19·9% for non-users (log-rank p<0·0001). GLP-1 receptor agonist use was associated with a 49% lower incidence of death-censored graft loss (adjusted subhazard ratio [aSHR] 0·51, 95% CI 0·36-0·71; p=0·0001) and 31% lower mortality (adjusted hazard ratio [aHR] 0·69, 95% CI 0·55-0·86; p=0·001). Inferences were robust when matched on survival time (death-censored graft loss aSHR 0·53, 95% CI 0·37-0·75; p=0·0005; mortality aHR 0·70, 95% CI 0·55-0·88; p=0·003). Safety endpoints were rare and not associated with GLP-1 receptor agonists, with the exception of diabetic retinopathy (aHR 1·49, 1·11-2·00; p=0·008). INTERPRETATION/CONCLUSIONS:GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings. FUNDING/BACKGROUND:National Institutes of Health.
PMID: 40056927
ISSN: 2213-8595
CID: 5808032

Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors

Menez, Steven; Kerr, Kathleen F; Cheng, Si; Hu, David; Thiessen-Philbrook, Heather; Moledina, Dennis G; Mansour, Sherry G; Go, Alan S; Ikizler, T Alp; Kaufman, James S; Kimmel, Paul L; Himmelfarb, Jonathan; Coca, Steven G; Parikh, Chirag R
BACKGROUND:Acute kidney injury (AKI) increases the risk for chronic kidney disease (CKD). We aimed to identify combinations of clinical variables and biomarkers that predict long-term kidney disease risk after AKI. METHODS:We analyzed data from a prospective cohort of 723 hospitalized patients with AKI in the Assessment, Serial Evaluation, and Subsequent Sequelae of AKI (ASSESS-AKI) Study. Using machine learning, we investigated 75 candidate predictors including biomarkers measured at three-month post-discharge follow-up to predict major adverse kidney events (MAKE) within three years, defined as a decline in eGFR ≥40%, development of end-stage kidney disease (ESKD), or death. RESULTS:The mean age of study participants was 64 ± 13 years, 68% were men, and 79% were of White race. Two hundred and four (28%) patients developed MAKE over 3 years of follow-up. Random forest and LASSO penalized regression models using all 75 predictors yielded area under the receiver-operating characteristic curve (AUC) values of 0.80 (95% CI: 0.69-0.91) and 0.79 (95% CI: 0.68-0.90) respectively. The most consistently selected predictors were albuminuria, soluble tumor necrosis factor receptor 1 (sTNFR1), and diuretic use. A parsimonious model using the top eight predictor variables showed similarly strong discrimination for MAKE (AUC = 0.78; 95% CI: 0.66-0.90). Clinical impact utility analyses demonstrated that the eight-predictor model would have 55% higher efficiency of post-AKI care (number needed to screen/follow-up for a MAKE event decreased from 3.55 to 1.97). For a kidney-specific outcome of eGFR decline or ESKD, a four-predictor model showed strong discrimination (AUC = 0.82; 95% CI: 0.68-0.96). CONCLUSION/CONCLUSIONS:Combining clinical data and biomarkers can accurately identify high-risk AKI patients, enabling personalized post-AKI care and improved outcomes.
PMID: 39671257
ISSN: 1555-905x
CID: 5761932

The hemodialysis unit: the place where everybody knows your name

Goldfarb, David S
PMID: 39878020
ISSN: 1473-6543
CID: 5780882

Trials and Tribulations: Responses of ChatGPT to Patient Questions About Kidney Transplantation

Xu, Jingzhi; Mankowski, Michal; Vanterpool, Karen B; Strauss, Alexandra T; Lonze, Bonnie E; Orandi, Babak J; Stewart, Darren; Bae, Sunjae; Ali, Nicole; Stern, Jeffrey; Mattoo, Aprajita; Robalino, Ryan; Soomro, Irfana; Weldon, Elaina; Oermann, Eric K; Aphinyanaphongs, Yin; Sidoti, Carolyn; McAdams-DeMarco, Mara; Massie, Allan B; Gentry, Sommer E; Segev, Dorry L; Levan, Macey L
PMID: 39477825
ISSN: 1534-6080
CID: 5747132

Establishing Research Priorities in Geriatric Nephrology: A Delphi Study of Clinicians and Researchers

Butler, Catherine R; Nalatwad, Akanksha; Cheung, Katharine L; Hannan, Mary F; Hladek, Melissa D; Johnston, Emily A; Kimberly, Laura; Liu, Christine K; Nair, Devika; Ozdemir, Semra; Saeed, Fahad; Scherer, Jennifer S; Segev, Dorry L; Sheshadri, Anoop; Tennankore, Karthik K; Washington, Tiffany R; Wolfgram, Dawn; Ghildayal, Nidhi; Hall, Rasheeda; McAdams-DeMarco, Mara
RATIONALE & OBJECTIVE/OBJECTIVE:Despite substantial growth in the population of older adults with kidney disease, there remains a lack of evidence to guide clinical care for this group. The Kidney Disease and Aging Research Collaborative (KDARC) conducted a Delphi study to build consensus on research priorities for clinical geriatric nephrology. STUDY DESIGN/METHODS:Asynchronous modified Delphi study. SETTING & PARTICIPANTS/METHODS:Clinicians and researchers in the US and Canada with clinical experience and/or research expertise in geriatric nephrology. OUTCOME/RESULTS:Research priorities in geriatric nephrology. ANALYTICAL APPROACH/METHODS:In the first Delphi round, participants submitted free-text descriptions of research priorities considered important for improving the clinical care of older adults with kidney disease. Delphi moderators used inductive content analysis to group concepts into categories. In the second and third rounds, participants iteratively reviewed topics, selected their top 5 priorities, and offered comments used to revise categories. RESULTS:Among 121 who were invited, 57 participants (47%) completed the first Delphi round and 48 (84% of enrolled participants) completed all rounds. After 3 rounds, the 5 priorities with the highest proportion of agreement were: 1) Communication and Decision-Making about Treatment Options for Older Adults with Kidney Failure (69% agreement), 2) Quality of Life, Symptom Management, and Palliative Care (67%), 3) Frailty and Physical Function (54%), 4) Tailoring Therapies for Kidney Disease to Specific Needs of Older Adults (42%), and 5) Caregiver and Social Support (35%). Health equity and person-centricity were identified as cross-cutting features that informed all topics. LIMITATIONS/CONCLUSIONS:Relatively low response rate and limited participation by private practitioners and older clinicians and researchers. CONCLUSIONS:Experts in geriatric nephrology identified clinical research priorities with the greatest potential to improve care for older adults with kidney disease. These findings provide a roadmap for the geriatric nephrology community to harmonize and maximize the impact of research efforts.
PMID: 39603330
ISSN: 1523-6838
CID: 5759122

Pain Coping Skills Training for Patients Receiving Hemodialysis: The HOPE Consortium Randomized Clinical Trial

Dember, Laura M; Hsu, Jesse Y; Mehrotra, Rajnish; Cavanaugh, Kerri L; Kalim, Sahir; Charytan, David M; Fischer, Michael J; Jhamb, Manisha; Johansen, Kirsten L; Becker, William C; Pellegrino, Bethany; Eneanya, Nwamaka D; Schrauben, Sarah J; Pun, Patrick H; Unruh, Mark L; Morasco, Benjamin J; Mehta, Mansi; Miyawaki, Nobuyuki; Penfield, Jeffrey; Bernardo, Leah; Brintz, Carrie E; Cheatle, Martin D; Doorenbos, Ardith Z; Heapy, Alicia A; Keefe, Francis J; Krebs, Erin E; Kuzla, Natalie; Nigwekar, Sagar U; Schmidt, Rebecca J; Steel, Jennifer L; Wetmore, James B; White, David M; Kimmel, Paul L; Cukor, Daniel
IMPORTANCE/UNASSIGNED:Chronic pain is common among individuals with dialysis-dependent kidney failure. OBJECTIVE/UNASSIGNED:To evaluate the effectiveness of pain coping skills training (PCST), a cognitive behavioral intervention, on pain interference. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This multicenter randomized clinical trial of PCST vs usual care was conducted across 16 academic centers and 103 outpatient dialysis facilities in the US. Adults undergoing maintenance hemodialysis and experiencing chronic pain were randomly assigned to PCST or usual care in a 1:1 ratio. Participants were followed in the trial for 36 weeks. Enrollment began on January 4, 2021, and follow-up ended on December 21, 2023. INTERVENTIONS/UNASSIGNED:PCST consisting of 12 weekly coach-led sessions via video or telephone conferencing, followed by 12 weeks of daily interactive voice response sessions. Usual care had no trial-driven pain intervention. MAIN OUTCOMES/UNASSIGNED:The primary outcome was pain interference measured with the Brief Pain Inventory (BPI) Interference subscale (score range of 0-10, with higher scores indicating more pain interference). Secondary outcomes included pain intensity, pain catastrophizing, quality of life, depression, and anxiety. RESULTS/UNASSIGNED:A total of 643 participants (mean [SD] age, 60.3 [12.6] years; 288 [44.8%] female) were randomized, with 319 assigned to PCST and 324 assigned to usual care. At week 12 (primary end point), the PCST group had a larger reduction in the BPI Interference score than the usual care group (between-group difference, -0.49; 95% CI, -0.85 to -0.12; P = .009). The effect persisted at week 24 (between-group difference in BPI Interference score, -0.48; 95% CI, -0.86 to -0.11) but was diminished at week 36 (between-group difference in BPI Interference score, -0.34; 95% CI, -0.72 to 0.04). A decrease in BPI Interference score greater than 1 point (minimal clinically important difference) occurred in 143 of 281 participants (50.9%) in the PCST group vs 108 of 295 participants (36.6%) in the usual care group at 12 weeks (odds ratio, 1.79; 95% CI, 1.28-2.49) and 142 of 258 participants (55.0%) in the PCST group vs 113 of 264 participants (42.8%) in the usual care group at 24 weeks (odds ratio, 1.59; 95% CI, 1.13-2.24). Favorable changes with PCST were also apparent for secondary outcomes of pain intensity, quality of life, depression, and anxiety at weeks 12 and/or 24, as well as for pain catastrophizing at weeks 24 and 36. CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this randomized clinical trial of patients undergoing maintenance hemodialysis, PCST had benefits on pain interference and other pain-associated outcomes. While the effect on the overall cohort was of modest magnitude, the intervention resulted in a clinically meaningful improvement in pain interference for a substantial proportion of participants. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT04571619.
PMID: 39786400
ISSN: 2168-6114
CID: 5781482

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Jaffe, Ian S; Runström, Anna; Tatapudi, Vasishta S; Weldon, Elaina P; Deterville, Cecilia L; Dieter, Rebecca A; Montgomery, Robert A; Lonze, Bonnie E; Mangiola, Massimo
BACKGROUND/UNASSIGNED:Imlifidase is an IgG-cleaving endopeptidase conditionally approved in Europe for desensitization of highly sensitized patients before kidney transplantation. We present 5-y outcomes and donor-specific antibody (DSA) levels for clinical trial participants from a single site who received imlifidase for desensitization before incompatible transplantation (NCT02790437). METHODS/UNASSIGNED:Imlifidase was administered up to 24 h before living or deceased donor kidney transplantation. DSAs were monitored before transplantation, at days 7 and 28, and at 5 y posttransplant. RESULTS/UNASSIGNED:At 5 y, 7 of 8 participants were alive. One of these 7 had suboptimal graft function secondary to donor-derived disease but remained dialysis independent. Three participants had antibody-mediated rejection (AMR), which occurred in the first 30 d in all cases and was successfully treated. No new episodes of suspected or biopsy-proven AMR occurred after 30 d posttransplant. Seven participants had DSA rebound. DSAs commonly persisted 5 y posttransplant, although they were generally lower strength compared with pre-imlifidase. Dilution studies of sensitized serum enabled the identification of lower AMR risk phenotypes for persisting DSAs. Severe and/or opportunistic infections were not observed at greater than expected frequency. CONCLUSIONS/UNASSIGNED:Five-year outcomes of imlifidase-enabled incompatible transplants are overall favorable. DSA rebound is common, but antibody strength lessens in the long term, and longitudinally persisting DSAs did not lead to premature graft failure.
PMCID:11723687
PMID: 39802198
ISSN: 2373-8731
CID: 5776182

Weight Loss Intentionality and Frailty are Associated with Pre-Kidney Transplant Outcomes

Ghildayal, Nidhi; Hong, Jingyao; Liu, Yi; Li, Yiting; Cockey, Samuel G; Ali, Nicole M; Mathur, Aarti; Orandi, Babak; Segev, Dorry L; McAdams-DeMarco, Mara
KEY POINTS:In frail kidney transplant (KT) candidates with obesity, unintentional weight loss preceding KT evaluation is associated with lower chance of listing. In frail candidates with obesity, both unintentional and intentional weight loss is associated with higher waitlist mortality. Results suggest that in frail candidates with obesity, careful supervision of weight loss prior to KT should be considered, emphasizing strategies to preserve muscle mass and function. BACKGROUND:Unintentional weight loss, a hallmark of frailty, predicts worse post–kidney transplantation (KT) outcomes. However, weight loss in candidates with obesity is often recommended to enhance transplant eligibility. We tested whether pre-evaluation weight change is associated with listing/waitlist mortality, considering intentionality and frailty. METHODS:) enrolled in a prospective multicenter cohort study. We estimated the association between pre-evaluation weight change (stable, gain, unintentional/intentional loss) with chance of listing/waitlist mortality using Cox proportional hazards/competing-risks models. RESULTS:Among candidates with obesity, 48% had stable weight, 17% had weight gain, 16% had unintentional weight loss, and 20% had intentional weight loss over the year before evaluation. Among frail candidates with obesity, stable weight was associated with a 27% lower chance of listing (adjusted hazard ratio [aHR], 0.73; 95% confidence intervals [CI], 0.55 to 0.96), weight gain with a 47% lower chance of listing (aHR, 0.53; 95% CI, 0.34 to 0.80), and unintentional weight loss with a 48% lower chance of listing (aHR, 0.52; 95% CI, 0.32 to 0.84) compared with nonfrail candidates with stable weight. However, in frail candidates with obesity, intentional weight loss was not associated with a significantly lower chance of listing compared with nonfrail candidates with stable weight. In addition, among frail candidates with obesity, stable weight (adjusted subhazard ratio [aSHR], 1.72; 95% CI, 1.01 to 2.90), unintentional weight loss (aSHR, 2.78; 95% CI, 1.23 to 6.27), and intentional weight loss (aSHR, 2.26; 95% CI, 1.05 to 4.85) were associated with higher waitlist mortality compared with nonfrail candidates with stable weight. Among nonfrail candidates, no associations were observed for weight change and frailty status with either chance of listing or waitlist mortality. CONCLUSIONS:Among frail candidates with obesity, unintentional pre-KT weight loss is associated with a lower chance of listing; however, any weight loss is associated with higher waitlist mortality. Our findings suggest that frail candidates with obesity may benefit from clinician supervision of pre-KT weight loss.
PMCID:11835156
PMID: 39621583
ISSN: 1555-905x
CID: 5804292